Sartorius rises after UBS ups rating to 'buy', on expected accelerating revenue growth

Sartorius AG

20/08/2026 11:03

** Shares in German biopharma supplier Sartorius SATG_p.DE rise 5% after UBS upgraded the stock to "buy" from "neutral", expecting the company's revenue growth to accelerate in the 2027-2029 timeframe.
** UBS says Sartorius's sales growth for 2027-2029 will be driven by demand for bioprocess consumables, biologics pipelines and biosimilar production volumes
** "The onshoring of US biomanufacturing should drive a bolus of Bioprocess equipment demand from H2 2027," the broker said
** UBS expects signs of rebounding orders for equipment to start building by H1 2027, with shipments from H2 2027
** The analyst forecasts Sartorius will achieve a compound annual EBITDA growth rate of 12% through 2030, compared to an average of 8% for its peers
** UBS set a target price of €300 ($351) a share for Sartorius; on Thursday, Sartorius' stock closed at €246.60 a share


($1 = 0.8542 euros)

 (Reporting by Basile Day)
 ((Basile.day@thomsonreuters.com))